@article {1430522,
	title = {Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study},
	journal = {Acta Diabetol},
	volume = {56},
	number = {7},
	year = {2019},
	month = {2019 Jul},
	pages = {777-784},
	abstract = {AIMS: To describe and compare the functional and anatomical outcomes of untreated and treated diabetic macular edema (DME) in eyes with very good baseline visual acuity (VA) in a real-world setting. METHODS: A 12-month, retrospective, multicenter, observational cohort study, including DME patients with baseline visual acuity (VA) <= 0.1 logMAR (>= 20/25 Snellen) and central subfield thickness (CST) \&gt; 250\&nbsp;{\textmu}m with intra- and/or subretinal fluid seen on optical coherence tomography. RESULTS: A total of 249 eyes were included, of which 155 were treated and 94 were non-treated during follow-up. Most eyes maintained vision (VA gain or VA loss \&lt; 5 letters) at 12\&nbsp;months (treated: 58.1\%; non-treated: 73.4\%). In non-treated eyes with stable VA within the first 6\&nbsp;months, VA was maintained throughout the follow-up in most cases (86.3\%). In non-treated eyes with VA loss >= 5 letters within 6\&nbsp;months (36.7\%), further observation led to worse visual outcome than treatment (- 4.2 vs. - 7.8 letters, p = 0.013). In eyes in which treatment was initiated at baseline (n = 102), treatment with 8-12 anti-VEGF injections led to better visual outcome compared to treatment with less injections (- 0.3 {\textpm} 3.6 letters vs. - 3.8 {\textpm} 6.2 letters, p = 0.003). CONCLUSION: In a real-world setting, the majority of DME patients with very good VA maintained vision at 12\&nbsp;months, regardless of whether the DME was treated or not. This study supports close observation of eyes with DME and very good VA with consideration of treatment when a one line drop in vision is observed.},
	issn = {1432-5233},
	doi = {10.1007/s00592-019-01310-z},
	author = {Busch, Catharina and Fraser-Bell, Samantha and Zur, Dinah and Rodr{\'\i}guez-Vald{\'e}s, Patricio J and Cebeci, Zafer and Lupidi, Marco and Fung, Adrian T and Gabrielle, Pierre-Henry and Giancipoli, Ermete and Chaikitmongkol, Voraporn and Okada, Mali and La{\'\i}ns, In{\^e}s and Santos, Ana Rita and Kunavisarut, Paradee and Sala-Puigdollers, Anna and Chhablani, Jay and Ozimek, Malgorzata and Hilely, Assaf and Unterlauft, Jan Darius and Loewenstein, Anat and Iglicki, Matias and Rehak, Matus and International Retina Group}
}
